Today: 27 June 2026
BAE Systems Shares Slip Despite Buyback and Higher Broker Target as Defence Rally Cools
6 March 2026
2 mins read

BAE Systems Shares Slip Despite Buyback and Higher Broker Target as Defence Rally Cools

LONDON, March 6, 2026, 08:11 GMT

  • Berenberg bumped its target on BAE Systems up to 2,300 pence from 2,000, sticking with its hold call. The broker pointed out the stock’s 32% climb since the start of 2026.
  • BAE picked up 97,895 shares for cancellation on March 4, as part of its ongoing buyback, paying an average price of 2,237.12 pence each, according to a filing.
  • The company just posted its best-ever results for 2025, notching an order backlog of 83.6 billion pounds, and is projecting more growth this year.

BAE Systems settled at 2,150 pence on Thursday, pulling back despite Berenberg lifting its price target and news of further buybacks under the company’s ongoing share repurchase programme.

The decline stings, given BAE’s standing as one of the top-performing European defence names this year. According to Berenberg, shares have gained 32% since the beginning of 2026. Still, the bank stuck with its hold recommendation. It did nudge up its price target to 2,300 pence from 2,000, suggesting only a bit of further upside from here.

Pressure came from across the board. The FTSE 100 slipped to its lowest in three weeks Thursday, dragged down as surging bond yields and a spike in oil prices—triggered by the Middle East conflict—led investors to dial back expectations for a Bank of England rate cut in March.

BAE picked up 97,895 ordinary shares on March 4, paying a volume-weighted average of 2,237.12 pence each, according to a Thursday filing. That pushes the total for the second leg of its buyback up to 18.3 million shares. The shares will be cancelled, the company said.

The broker’s call came a little more than two weeks after BAE, the UK’s top defence group, posted a 12% bump in full-year operating profit, with sales at a record 30.66 billion pounds and orders piling up to 83.6 billion pounds. Chief Executive Charles Woodburn called it a “new era of defence spending” and pointed to faster innovation, driven by increased threats that “fast tracked more than a decade’s worth” of technology change. BAE is looking for 7% to 9% sales growth, and 9% to 11% operating profit growth, by 2026. Reuters

Morgan Stanley, in a note earlier this week, flagged BAE as well positioned should U.S. military outlays pick up, noting that roughly 45% of its revenue comes from the U.S. and close to 10% from the Gulf region. The bank also pointed to Leonardo, Dassault Aviation, and Kongsberg as European players that stand to gain if defence spending ramps up.

Rivals haven’t missed out. Leonardo landed a 1 billion-pound British contract to make 23 medium-lift military helicopters, announced March 2. Over at Thales, air-defence demand gave earnings a boost, according to a March 3 statement. Chief Executive Patrice Caine pointed to the latest Gulf crisis as proof that geopolitics is pushing countries to ramp up security spending.

But it’s not a one-way street. Morgan Stanley pointed out risks tied to logistics, global supply chains, energy prices, and air traffic in the Middle East. Caine put it bluntly: “Nobody knows today how it will evolve.” Slower government orders or a quick reversal in the conflict-fueled rally for defence stocks could make BAE’s next move up tougher to pull off. Sharecast

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

27 June 2026
Lucid surged 15.6% Friday, adding $312 million in equity value—almost double the $158 million in annualized savings from this week’s restructuring plan that cut 18% of its U.S. workforce. Friday’s volume equaled 54% of reported short interest, but the rally outpaced cost-cutting fundamentals, leaving less room for further gains based solely on headcount cuts.
Court ruling on student loans hits private lenders’ health grad loan push

Court ruling on student loans hits private lenders’ health grad loan push

27 June 2026
Judge blocks narrow “professional degree” rule, letting more health-care grad students keep higher federal loan caps; $7.87B in 2023-24 borrowing above new limits remains in federal market, trimming but not eliminating the $4.5B-$5B annual private loan growth Sallie Mae projected from Grad PLUS loan cuts.
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom
Previous Story

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 09.03.2026

Go toTop